Active externally funded projects
HSØ, Functional studies of genetic susceptibility and melanoma risk genes, 01.01.14-31.12.16, NOK 3 099 000.-.
HSØ , Ovarian Cancer: circumventing chemoresistance in metastatic and recurrent disease: 01.01.16-31.12.2018, NOK 3 016 000.-.
HSØ; Novel diagnostic Pipeline for precision medicine in melanoma, 01.08.16-31.07.19: NOK 9 000 000,-.
EU Horizon 220, MSCA -1TN-2014, Development of an iPSC based model to study melanoma tumorigenesis, 01.01.16-01.06.2019, EUR 541 854.-
Cancer Society: Identification of novel prognostic factors and therapeutic targets in vulvar cancer, 01.01 2014- 31.12.2016, NOK 2 470 000.-
1. Prof. Reuven Reich, Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
2. Profs. Tian-Li Wang and Ie-Ming Shih, Department of Pathology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA.
3. Prof. Jean-Paul Thierry, Cancer Science Institute (CSI) and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, MD6 Centre for Translational Medicine, 117599 Singapore; Institute of Molecular and Cell Biology (IMCB) A*STAR, Proteos 138673, Singapore.
4. Prof. Jeremias Wohlschlaeger, Department of Pathology, University Hospital Essen, Essen, 45147, Germany